処理中

しばらくお待ちください...

設定

設定

出願の表示

1. EP2194141 - METHOD OF PREDICTING DRUG-INDUCED PHOSPHOLIPIDOSIS

官庁
欧州特許庁(EPO)
出願番号 08835363
出願日 03.10.2008
公開番号 2194141
公開日 09.06.2010
公報種別 A4
IPC
C12Q 1/34
C化学;冶金
12生化学;ビール;酒精;ぶどう酒;酢;微生物学;酵素学;突然変異または遺伝子工学
Q酵素,核酸または微生物を含む測定または試験方法;そのための組成物または試験紙;その組成物を調製する方法;微生物学的または酵素学的方法における状態応答制御
1酵素,核酸または微生物を含む測定または試験方法;そのための組成物;そのような組成物の製造方法
34加水分解酵素を含むもの
G01N 33/15
G物理学
01測定;試験
N材料の化学的または物理的性質の決定による材料の調査または分析
33グループG01N1/00~G01N31/00に包含されない,特有な方法による材料の調査または分析
15医薬
G01N 33/50
G物理学
01測定;試験
N材料の化学的または物理的性質の決定による材料の調査または分析
33グループG01N1/00~G01N31/00に包含されない,特有な方法による材料の調査または分析
48生物学的材料,例.血液,尿;血球計
50生物学的材料,例.血液,尿,の化学分析;生物学的特異性を有する配位子結合方法を含む試験;免疫学的試験
CPC
C12Q 1/34
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
34involving hydrolase
G01N 33/5014
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
5005involving human or animal cells
5008for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
5014for testing toxicity
G01N 33/502
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
5005involving human or animal cells
5008for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
502for testing non-proliferative effects
G01N 33/5023
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
5005involving human or animal cells
5008for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
502for testing non-proliferative effects
5023on expression patterns
G01N 2333/92
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
90Enzymes; Proenzymes
914Hydrolases (3)
916acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
918Carboxylic ester hydrolases (3.1.1)
92Triglyceride splitting, e.g. by means of lipase
G01N 2333/924
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
90Enzymes; Proenzymes
914Hydrolases (3)
924acting on glycosyl compounds (3.2)
出願人 UNIV KYUSHU NAT UNIV CORP
ASTELLAS PHARMA INC
発明者 TANAKA YOSHITAKA
IKEDA KAZUHIKO
指定国 (国コード)
優先権情報 2007261125 04.10.2007 JP
発明の名称
(DE) VERFAHREN ZUR VORHERSAGE VON ARZNEIMITTELINDUZIERTER PHOSPHOLIPIDOSE
(EN) METHOD OF PREDICTING DRUG-INDUCED PHOSPHOLIPIDOSIS
(FR) PROCEDE DE PREDICTION D'UNE PHOSPHOLIPIDOSE INDUITE PAR LES MEDICAMENTS
要約
(EN) The present invention provides a method of predicting drug-induced phospholipidosis, comprising a step of contacting a mammalian cell with a test compound, a step of measuring extracellular and/or intracellular lysosomal enzyme level or activity, or measuring intracellular LC3 level, and a step of selecting a test compound that has enhanced extracellular secretion of the enzyme or increased the protein level as a compound capable of inducing drug-induced phospholipidosis.
(FR) La présente invention concerne un procédé de prédiction d'une phospholipidose induite par les médicaments, comprenant une étape de mise en contact de cellules de mammifère avec un composé test ; une étape de mesure de l'activité d'une enzyme lysosomiale à l'extérieur et/ou à l'intérieur des cellules, ou de mesure de la quantité de LC3 présente dans les cellules ; et une étape de sélection d'un composé test favorisant la sécrétion de l'enzyme hors des cellules ou entraînant une augmentation de la quantité de protéine, en tant que composé capable d'induire une phospholipidose induite par les médicaments.